Abstract
President Donald J. Trump’s pick to lead the Food & Drug Administration, Scott Gottlieb, wants to get new drugs, including low-cost generics, on the market faster. A physician with leadership experience at FDA, Gottlieb is a favorite of the pharmaceutical industry. But his close ties with drug companies have some critics raising concerns about potential conflicts of interest. Gottlieb knows FDA. He was FDA’s deputy commissioner for medical and scientific affairs under former president George W. Bush. Gottlieb speaks often about FDA regulations as a fellow at the American Enterprise Institute, a conservative think tank, and he sits on the boards of many pharmaceutical companies, including GlaxoSmithKline. He also knows Wall Street well. Gottlieb is a partner at New Enterprise Associates, one of the largest venture capital funds in the world. Pharmaceutical companies, including makers of generic drugs, are welcoming Gottlieb’s nomination. “His extensive experience as a physician and breadth
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call